-
公开(公告)号：US11986477B2
公开(公告)日：2024-05-21
申请号：US18387180
申请日：2023-11-06
发明人： Baoyuan Zhang , Xuebin Liu , Jiaming Gao , Ping Zhang , Ran Pang , Zaiqi Wang
IPC分类号： A61K31/506 , A61P35/00
CPC分类号： A61K31/506 , A61P35/00
摘要： The present disclosure relates to the combination of IN10018 and an epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of tumors.
-
公开(公告)号：US20230079055A1
公开(公告)日：2023-03-16
申请号：US17797867
申请日：2021-01-29
发明人： Zaiqi WANG , Jiangwei ZHANG
IPC分类号： A61K31/506 , A61K31/704 , A61K9/127 , A61K31/337 , A61P35/00
摘要： The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
-
公开(公告)号：US20210230171A1
公开(公告)日：2021-07-29
申请号：US15734986
申请日：2019-06-03
发明人： Zaiqi WANG , Lihu YANG
IPC分类号： C07D487/14 , A61K9/00
摘要： The present invention relates to a selective A2A receptor antagonist, and in particular to a selective A2A receptor antagonist of Formula (I), a pharmaceutical composition comprising the antagonist, use of the antagonist in manufacturing a medicament and in treatment of a disease: wherein the groups in Formula (I) are defined as in the specification.
-
公开(公告)号：US12115160B2
公开(公告)日：2024-10-15
申请号：US18454922
申请日：2023-08-24
发明人： Jun Jiang , Shuang Xie , Jiangwei Zhang , Zaiqi Wang
IPC分类号： A61K31/506 , A61K31/704 , A61P35/00
CPC分类号： A61K31/506 , A61K31/704 , A61P35/00
摘要： The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
-
公开(公告)号：US12064431B2
公开(公告)日：2024-08-20
申请号：US17780397
申请日：2020-11-27
发明人： Zaiqi Wang , Jiangwei Zhang , Jun Jiang , Baoyuan Zhang
IPC分类号： A61P35/00 , A61K31/513 , A61K31/519
CPC分类号： A61K31/513 , A61K31/519 , A61P35/00
摘要： The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
-
公开(公告)号：US12059421B2
公开(公告)日：2024-08-13
申请号：US18221588
申请日：2023-07-13
发明人： Zaiqi Wang , Jiangwei Zhang , Jun Jiang , Baoyuan Zhang
IPC分类号： A61K31/513 , A61K31/519 , A61P35/00
CPC分类号： A61K31/513 , A61K31/519 , A61P35/00
摘要： The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
-
公开(公告)号：US20230372340A1
公开(公告)日：2023-11-23
申请号：US18221588
申请日：2023-07-13
发明人： Zaiqi Wang , Jiangwei Zhang , Jun Jiang , Baoyuan Zhang
IPC分类号： A61K31/513 , A61P35/00 , A61K31/519
CPC分类号： A61K31/513 , A61P35/00 , A61K31/519
摘要： The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
-
公开(公告)号：US20240307395A1
公开(公告)日：2024-09-19
申请号：US18674295
申请日：2024-05-24
发明人： Zaiqi Wang , Jiangwei Zhang , Jun Jiang , Baoyuan Zhang , Xuebin Liu
IPC分类号： A61K31/513 , A61K31/519 , A61P35/00
CPC分类号： A61K31/513 , A61K31/519 , A61P35/00
摘要： The present invention relates to a method for treating a tumor such as a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
-
公开(公告)号：US20240261285A1
公开(公告)日：2024-08-08
申请号：US18633164
申请日：2024-04-11
发明人： Zaiqi Wang , Jiangwei Zhang
IPC分类号： A61K31/506 , A61K31/7048 , A61K33/243 , A61P35/00
CPC分类号： A61K31/506 , A61K31/7048 , A61K33/243 , A61P35/00
摘要： The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
-
公开(公告)号：US20230390289A1
公开(公告)日：2023-12-07
申请号：US18454922
申请日：2023-08-24
发明人： Jun Jiang , Shuang Xie , Jiangwei Zhang , Zaiqi Wang
IPC分类号： A61K31/506 , A61K31/704 , A61P35/00
CPC分类号： A61K31/506 , A61K31/704 , A61P35/00
摘要： The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.015 秒)
